Acquisitions, Mergers & PartnershipsAM IndustryBioprinting

CELLINK, MatTek and Visikol launch 3D Bioprinting CRO

The three BICO companies have joined forces to present offerings in biomaterials and cell analysis

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

BICO subsidiaries CELLINK, MatTek and Visikol launched a collaboration combining the expertise of the three companies to establish a 3D bioprinting CRO (contract research organization) with comprehensive bioprinting services. By utilizing a CRO, CELLINK, MatTek and Visikol have granted their customers access to offerings from all three companies. The partnership furthers the BICO groups’ commitment to its Bio Convergence agenda by identifying synergies in business area Bioprinting to offer customers solutions trending toward the future of health.

CELLINK, MatTek and Visikol launch 3D Bioprinting CRO“We are very excited to be joining forces with MatTek and Visikol to offer contract research combining our expertise in cell culture, advanced tissue models, 3D bioprinting, imaging, digital pathology and advanced cell culture assay,” said Itedale Namro Redwan, CSO of CELLINK. “We are hoping that our joint effort will contribute to minimizing the use of animal models in research.”

The partnership includes MatTek, which brings decades of primary cell isolation experience; CELLINK, which brings a wealth of bioprinting design and biomaterial development expertise; and Visikol: experts in assay development, and in bridging the gap between 3D models and animal studies.

“By combining the expertise areas of CELLINK, MatTek and Visikol, we’re able to offer researchers a thorough bioprinting experience,” said Michael Johnson, CEO of Visikol. “I’m very proud of this offering and look forward to what we’re able to achieve.”

CELLINK, MatTek and Visikol launch 3D Bioprinting CRO The joint 3D bioprinting CRO will offer custom-designed tissue constructs bioprinted by CELLINK. These constructs can either be delivered to customers’ labs for analysis, or customers can select to have BICO scientists run experiments and deliver a detailed report. Additionally, alongside custom bioprinting, this partnership will enable customers to leverage established off-the-shelf 3D tissue models and toxicology services from MatTek, and customers will have access to drug toxicity testing and disease modelling platforms from Visikol’s pre-existing services.

“Our complementary technologies and expertise make this partnership with CELLINK and Visikol a natural fit for us,” said Alex Armento, CEO of MatTek. “We’re thrilled to increase our product and service offerings and expand access to more human-relevant testing methods for our customers.”

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he co-founded London-based 3dpbm. Today the company publishes the leading news and insights websites 3D Printing Media Network and Replicatore, as well as 3D Printing Business Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*